chapter  6
3 Pages

Lipids, hormone replacement therapy and cardiovascular disease

ByDavid Crook

The basic concept of ‘biochemical risk’ for

arterial disease has now been validated by

randomized placebo-controlled studies of

statin and fibrate drugs. Protection from

CHD has been demonstrated when such

drugs are used to normalize plasma levels of

low density lipoproteins (LDL), fasting

triglycerides or high density lipoproteins

(HDL).3 As yet there is no evidence for a

clinical benefit from reducing plasma levels of

lipoprotein(a) (Lp(a)), but such studies are

difficult to conduct in the absence of specific

Lp(a)-lowering therapies.